|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||201.42 - 209.25|
|52 Week Range||184.50 - 256.80|
|PE Ratio (TTM)||6.24|
|Dividend & Yield||2.80 (1.30%)|
|1y Target Est||N/A|
Allergan is advancing a nonalcoholic steatohepatitis drug into Phase 3 testing that likely won't get FDA approval.
In a filing to the U.S. Patent Trial and Appeal Board, the Saint Regis Mohawk Tribe asked that Mylan's case seeking to invalidate Allergan's patents on dry-eye medicine Restasis be thrown out on the grounds that the board has no jurisdiction over the tribe. The move was expected after Allergan announced on Sept. 8 that it had transferred Restasis patents to the tribe in order to protect them from administrative challenges.
Pressing ahead after mixed data is usually a recipe for failure.